top of page

Nee Soon Clinic

25 Jan 2026

How Much Does Tirzepatide Cost in Singapore?

One of the most common questions asked before starting a weight-loss injection is a simple one: how much does it cost?


This article answers the cost question directly, then explains what sits behind the number: what a weight-loss injection program includes, who is eligible, what results the clinical evidence supports, and how dosing affects the total cost over the entire treatment journey.


Short answer: At Nee Soon Clinic, the tirzepatide weight-loss programme starts from $360, covering the doctor's consultation, the medication and health coaching; lab tests are charged separately. Published prices elsewhere in Singapore vary widely by dose and by what is included. Treatment is prescription-only and is generally paid for privately.


Medical Weight Loss Injection Tirzepatide Clinical Study

UP TO

20.9%

Average weight loss

Published clinical trial data

UP TO

33.9%

Average fat mass reduction

Published clinical trial data

REDUCE

18.5cm

Average waist circumference

Published clinical trial data

ACHIEVE

95%

Pre-diabetes to normal sugar level

Published clinical trial data

UP TO

7.2mmHg

Average systolic BP reduction

Published clinical trial data

UP TO

24.8%

Average triglyceride reduction

Published clinical trial data

Figures are based on the SURMOUNT-1 clinical trial of tirzepatide in adults, at the highest dose (15 mg) over 72 weeks. Individual results vary.


Medical Weight Loss Program with Tirzepatide Cost in Singapore

Starts at

$360


WHAT IS INCLUDED

✓ Doctor consultation and medical assessment

✓ Prescription medication and dose optimisation

✓ Nutrition and lifestyle guidance with follow-up monitoring of treatment response and tolerability


Ancillary laboratory tests if performed are charged separately.

Benefits

Medically supervised


WHY CHOOSE US

  • Comprehensive Doctor Assessment

    Know if weight-loss medication is right for you.


  • Experienced Medical Guidance

    To support weight loss and reduce side effects.


  • Personalised Weight Loss Plan

    A plan tailored to your goals.


  • Continuous Support & Monitoring

    Professional guidance throughout your weight-loss journey.


  • Long-Term Health Focus

    Work towards better health outcomes.

At Nee Soon Clinic Singapore, tirzepatide weight loss program starts from $360. This bundles the doctor consultation and assessment, the injection medication itself, and personalised health coaching into a single cost. Ancillary laboratory tests, if performed, are charged separately.


Mounjaro Cost in Singapore

Is this programme suitable for you?

You may be suitable if:

  • your BMI is 30 or above, or

  • your BMI is 27 or above with diabetes, high blood pressure, high cholesterol or sleep apnoea

A doctor’s consultation confirms whether treatment is right for you. The programme starts from $360 nett, including consultation, medication and coaching.

See what the programme includes →

Ask us on WhatsApp →


Tirzepatide Cost in Singapore: The Quick Answer

Question

Practical answer

What that includes

Doctor consultation and assessment, injection medication, and personalised health coaching

Charged separately

Ancillary laboratory tests, if performed

Wider market range

Published Singapore clinic pricing varies widely depending on dose

Is it subsidised?

Treatment prescribed for weight management is generally paid privately

Can MediSave be used?

Weight-management indications are typically not claimable

Who is eligible

BMI 30 or above, or BMI 27 or above with a weight-related condition

How often injected

Once weekly, starting at 2.5 mg and increased gradually

Typical weight loss

Around 5-8% at three months and 10-12% at six months when paired with sustained coaching

Prescription status

Prescription-only; requires medical consultation before supply

Pricing accurate as of August 2026 and subject to change. Final costs are confirmed at consultation.



How Much Does Tirzepatide Cost in Singapore?

The published clinic pricing for Tirzepatide varies considerably across various medical clinics in Singapore

Dose tier

Commonly published monthly range

Starting dose (2.5 mg)

Approximately $380 to $600

Mid dose (5 to 7.5 mg)

Approximately $700 to $900

Higher maintenance (10 to 15 mg)

Approximately $900 to $1,500


Three factors explain most of that spread. The first is the prescribed dose, since higher doses contain more active medication. The second is whether consultation and follow-up review are bundled into the quoted figure or charged on top. The third is whether any structured support, such as nutrition, activity and habit coaching, is included at all.


This is why comparing headline figures between clinics can be misleading. A lower medication-only price may exclude the assessment, the dose reviews and the follow-up care that make treatment safe and effective. When comparing options, it is worth asking what a quoted price actually covers over a full course of treatment rather than for a single month.


understanding mounjaro cost in singapore


What the Cost Actually Covers

A tirzepatide programme is a medical treatment pathway rather than a product purchase. Each component has a clinical purpose:

  • Doctor consultation - assessment of BMI, metabolic risk and eligibility, and confirmation that treatment is appropriate.

  • Injection medication - tirzepatide prescribed and dosed under medical supervision.

  • Dose titration - gradual escalation to limit gastrointestinal side effects.

  • Health coaching - nutrition, activity and habit support so results are maintained beyond the medication.

  • Follow-up review - monitoring of response, tolerance and safety, with dose adjustment as needed.


Coaching in particular is worth noting. The evidence on this class of medication consistently shows that appetite regulation fades once treatment stops, so the habits built during treatment determine how much of the result is retained afterwards. You can read more about our medically supervised weight-loss injection programme and what each stage involves.



Am I Eligible for Tirzepatide?

Eligibility is determined clinically, not financially. Meeting the criteria matters more than willingness to pay, and a consultation exists to establish whether treatment is appropriate and safe.


Generally suitable

  • BMI of 30 or above

  • BMI of 27 or above with a weight-related condition such as type 2 diabetes, hypertension, high cholesterol or sleep apnoea

  • Type 2 diabetes (a separate indication, assessed by your doctor)


Generally not suitable

  • Pregnancy or breastfeeding

  • History of pancreatitis or certain endocrine cancers

  • Severe gastrointestinal conditions

  • BMI below 27 without type 2 diabetes


Existing medication also matters. Anyone already taking a sulphonylurea or insulin needs those doses reviewed, because combining them with tirzepatide can lower blood sugar further than intended. Kidney function, liver function and gallbladder history are also assessed before starting.



GETTING STARTED

Three steps to begin

01

Your first consultation

A full medical review at the clinic — weight and waist, blood pressure, blood sugar, medical history and any medication you already take. Your doctor confirms whether treatment is appropriate for you, starts you on the lowest dose, and supervises your first injection. Your coaching plan is set up the same visit.

02

Weekly treatment, with support in between

You inject once a week at home. Between visits, coaching handles the part that actually decides whether the weight stays off — meals, activity and everyday habits. If side effects or questions come up, you are not waiting until the next appointment to raise them.

03

Review, then adjust

At around four weeks your progress is reviewed properly: weight change, how well you are tolerating the dose, and whether it should step up or hold. Nothing is fixed at the start — the plan follows how you actually respond, not a script.



What Results Does the Tirzepatide Evidence Support?

Tirzepatide is a dual incretin receptor agonist that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual receptor activity distinguishes it from therapies targeting a single incretin pathway and has demonstrated clinically significant effects on weight reduction and metabolic parameters.


The physiological actions of GIP and GLP-1 extend beyond glycaemic regulation, involving complex interactions between pancreatic hormone secretion, central appetite pathways, gastrointestinal motility and energy homeostasis. GLP-1 receptor activation promotes glucose-dependent insulin secretion, suppresses glucagon secretion, delays gastric emptying and modulates hypothalamic pathways involved in appetite regulation. GIP receptor stimulation enhances insulinotropic activity and may contribute to improved adipose tissue and metabolic function.


Importantly, obesity is associated with complex physiological adaptations that influence appetite control, energy intake and weight maintenance. Following weight loss, compensatory changes in hormonal signalling and energy regulation may promote weight regain. By modulating incretin pathways involved in appetite and metabolic regulation, tirzepatide provides a pharmacological approach that targets some of the biological mechanisms contributing to persistent excess weight.


The most direct evidence comes from the SURMOUNT-5 trial, which compared tirzepatide against semaglutide head-to-head in adults with obesity without type 2 diabetes. Over 72 weeks, participants taking tirzepatide lost an average of 20.2% of body weight, compared with 13.7% for semaglutide, or approximately 22.8 kg against 15.0 kg. Waist circumference fell by an average of 18.4 cm compared with 13.0 cm. Gastrointestinal side effects leading to discontinuation were recorded less often with tirzepatide, at 2.7% against 5.6%.


These figures are trial averages across selected participants under trial conditions. They are not a prediction for any individual. Response depends on dose, adherence, tolerability, diet, activity, sleep, existing medical conditions and the quality of follow-up.


In practice, a more useful expectation is the trajectory typically seen when injections are paired with sustained coaching:


Timepoint

Typical weight reduction

What tends to change

3 months

5-8%

Appetite suppression and reduced cravings

6 months

10-12%

Improvements in blood sugar and blood pressure markers

12 months

15% or more

Strongest results where coaching has been sustained


For a fuller comparison of the injectable options available locally, see our overview of which weight-loss injection works best in Singapore.


mounjaro weight loss cost singapore


How Dosing Affects the Total Cost of Tirzepatide

Tirzepatide is started low and increased gradually. Treatment usually begins at 2.5 mg once weekly. After four weeks the dose is typically increased to 5 mg. Any further increases are made in 2.5 mg steps, with at least four weeks at the current dose before moving up. Maintenance doses are commonly 5, 10 or 15 mg, with 15 mg the maximum weekly dose.


Titration is not a formality. Escalating gradually gives the body time to adjust and reduces the nausea and other gastrointestinal effects that are most pronounced early in treatment.


Because higher doses contain more active medication, monthly cost commonly rises during titration and then settles once a maintenance dose is reached. This is why the cost of treatment is better understood over a full course than as a single monthly figure. It is worth adding that a higher dose is not automatically a better one. The appropriate dose is the one that balances effectiveness against tolerability.



Cost of Tirzepatide Side Effects

Common side effects. The most frequently reported adverse effects of tirzepatide involve the gastrointestinal system, including nausea, vomiting, diarrhoea, constipation, reflux symptoms, abdominal discomfort and reduced appetite. These effects are generally most noticeable during the initial treatment period or following dose escalation, as the gastrointestinal tract adapts to changes in incretin signalling and gastric motility.


In most patients, these symptoms are mild to moderate and can often be effectively managed through appropriate dose adjustment, medical supervision and adherence to dietary recommendations. Patient education plays an important role in improving treatment tolerability and maintaining long-term adherence.


Practical strategies that may help reduce side effects include:

  • Consuming smaller meals and avoiding large portions, as increased satiety may occur more rapidly during treatment

  • Eating slowly and stopping when comfortably full to avoid excessive gastric discomfort

  • Maintaining adequate fluid intake, particularly if experiencing vomiting, diarrhoea or reduced food intake

  • Ensuring sufficient protein intake to support preservation of lean muscle mass during weight reduction

  • Maintaining adequate dietary fibre intake to support bowel regularity and reduce constipation

  • Limiting very oily, high-fat or heavily spiced foods if these worsen nausea, reflux or abdominal discomfort

  • Developing mindful eating habits and adjusting meal patterns according to appetite changes


Gradual and individualised dose approach, combined with appropriate nutritional guidance, can greatly improve tolerability while allowing patients to achieve the intended therapeutic benefits of the weight loss injection treatment, while managing the costs of tirzepatide.


Less common but more serious. Pancreatitis, gallbladder problems, dehydration, and worsening kidney function in patients unable to keep fluids down. Prompt medical review is appropriate for severe abdominal pain, persistent vomiting, signs of dehydration or unusual weakness.


Interaction with diabetes medication. Tirzepatide lowers blood sugar. When it is added to a sulphonylurea or to insulin, the doses of those medications may need reducing to limit the risk of hypoglycaemia, and blood glucose self-monitoring becomes important.


Muscle preservation. Weight loss is not the same as fat loss. Rapid loss can include lean tissue, which affects strength, metabolic rate and the ability to maintain results afterwards. Adequate protein intake and resistance training during treatment help protect muscle.


A personalised approach to dose optimisation may also improve long-term affordability. Avoiding unnecessary dose escalation, managing side effects early and selecting the most appropriate treatment strategy can help patients achieve effective weight loss without incurring avoidable medication costs. Effective side effect management also contributes to cost-effective treatment by supporting adherence, reducing unnecessary dose adjustments and helping patients remain on the most appropriate regimen for their individual response.



Cost Effectiveness of Tirzepatide: Considering Value Beyond Medication Cost

The cost of tirzepatide treatment should be evaluated within the broader context of medical weight management rather than medication price alone.


Health technology assessments (HTAs) consider not only the direct cost of a therapy, but also its clinical effectiveness, impact on obesity-related complications, improvement in quality of life and potential long-term healthcare benefits.


National Institute for Health and Care Excellence (NICE) in the United Kingdom has assessed tirzepatide as a treatment option for weight management in adults meeting specific clinical criteria, recognising the substantial weight reduction demonstrated in clinical trials while applying restrictions on eligibility and a review if less than 5% of weight is lost after six months.


Published economic evaluations have demonstrated that tirzepatide can provide substantial health benefits through significant weight reduction and improvements in metabolic outcomes. Several cost-effectiveness analyses using health economic modelling have suggested that tirzepatide may provide favourable value compared with alternative pharmacological weight management strategies, particularly when considering improvements in quality-adjusted life years (QALYs), reduction in obesity-related disease burden and prevention of metabolic complications.


Tirzepatide vs Lifestyle Intervention Modelling studies comparing tirzepatide with lifestyle intervention alone have projected improvements in long-term health outcomes, including increased quality-adjusted life expectancy and reduced incidence of obesity-related conditions such as type 2 diabetes and cardiovascular disease.


Tirzepatide vs Anti-obesity medications Other analyses comparing tirzepatide with existing anti-obesity medications have reported favourable incremental cost-effectiveness ratios (ICERs), suggesting that tirzepatide may represent good value when assessed against commonly accepted willingness-to-pay thresholds, particularly when medication costs and long-term benefits are appropriately balanced.


Institute for Clinical and Economic Review (ICER) evaluated tirzepatide as part of its assessment of pharmacological treatments for obesity. The ICER assessment incorporated clinical outcomes, quality-adjusted life years (QALYs), healthcare costs and long-term value for money. The final evidence review concluded that tirzepatide provided substantial net health benefits compared with lifestyle modification alone, with economic modelling suggesting favourable long-term value under commonly used cost-effectiveness thresholds, although affordability and overall healthcare budget impact remain important considerations given the large population eligible for treatment


However, cost-effectiveness remains highly dependent on several factors, including medication pricing, treatment duration, patient characteristics, healthcare system and the threshold used by individual HTA bodies. Economic analyses have consistently highlighted that medication cost is a major determinant of value, and the greatest economic benefit is achieved when treatment is appropriately targeted towards patients who are most likely to experience meaningful and sustained clinical improvement.


Lowest Cost Effective Dose In clinical practice, cost-effective treatment does not necessarily mean selecting the lowest-cost medication or using the highest available dose. The most appropriate approach is to achieve meaningful and sustainable weight reduction with the lowest effective dose that provides adequate clinical response while maintaining tolerability.


  • Selecting patients who are most likely to benefit from therapy

  • Optimising dose escalation according to individual response

  • Reducing unnecessary dose increases and medication wastage

  • Managing side effects early to improve treatment adherence

  • Supporting strategies that maintain long-term results


Ultimately, the value of tirzepatide extends beyond short-term weight loss. When used as part of a structured medical weight management programme, appropriate treatment optimisation can help patients achieve clinically meaningful outcomes while balancing effectiveness, safety and long-term affordability.



Cost of Obtaining Tirzepatide Safely

Tirzepatide is a prescription-only medication in Singapore and should be obtained through a licensed medical provider following consultation. It is not an over-the-counter product, and it is not appropriate to supply it without proper medical assessment.


Unverified online sellers, informal resale channels and overseas grey imports carry real risks: counterfeit or substandard product, incorrect dosing, broken cold-chain storage, and no clinical follow-up if something goes wrong. Anyone offering prescription medication without a comprehensive medical consultation is not operating safely. The lowest price is not always the lowest overall risk or cost or effectiveness.


Selecting a reliable and medically supervised tirzepatide weight management provider can help patients optimise treatment outcomes, minimise avoidable costs and avoid unnecessary delays in achieving sustainable weight reduction.



Frequently Asked Questions


How much does tirzepatide cost in Singapore?

At Nee Soon Clinic Singapore, medical weight loss management program with tirzepatide cost from $360 onwards, including doctor consultation, injection medication and health coaching. Laboratory tests are charged separately. Published pricing elsewhere in Singapore varies widely depending on dose and what the quoted figure includes.


Is tirzepatide subsidised in Singapore?

Treatment prescribed for weight management is generally paid privately and is not included on subsidised drug lists. Cost arrangements may differ where treatment is prescribed for type 2 diabetes, which should be discussed at consultation.


Can I use MediSave to pay for it?

MediSave use depends on the indication and on clinic policy. Weight-management indications are typically not claimable.


Why can't a clinic quote one fixed price?

Because the dose changes during treatment and eligibility must be confirmed first. A single advertised figure would not reflect titration, review frequency or individual clinical needs. A bundled programme price addresses this by fixing the cost of a defined treatment period.


Does a higher dose mean better results?

Not necessarily. Dose optimisation depends on tolerance and individual response. The appropriate dose is the one that produces sustained appetite control without unacceptable side effects.


How long will I need to stay on treatment?

This depends on goals, response, tolerability and metabolic risk, and should be reviewed over time rather than fixed at the first consultation. Obesity and type 2 diabetes are chronic conditions, and many patients require ongoing management.


What happens to my weight if I stop?

Some weight regain is common once appetite regulation fades. Building maintenance habits during treatment rather than afterwards makes a measurable difference. See our article on what happens when you stop tirzepatide.


How does tirzepatide compare with semaglutide?

Tirzepatide acts on both GIP and GLP-1 pathways, while semaglutide acts on GLP-1 alone. In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight reduction over 72 weeks, at 20.2% against 13.7%.


Can I get treatment without a consultation?

No. Tirzepatide is prescription-only, and a consultation is required to confirm eligibility, check for contraindications and review existing medication before treatment can be supplied.


The Bottom Line (Cost vs Price approach to Tirzepatide in Singapore)


The true cost of tirzepatide treatment is not just the price of the medication. Safe and effective weight management also requires proper assessment, dose optimisation, side-effect management and ongoing medical support.


At Nee Soon Clinic Singapore, medical weight loss injection treatment program with tirzepatide starts from $360 onwards, including consultation, prescribed medication and weight management support. Laboratory investigations, when required, are charged separately. Treatment costs may vary over time depending on individual response, dosage requirements and treatment duration.


The most cost-effective approach is not simply choosing the lowest price, but achieving meaningful weight reduction with the right treatment plan, appropriate dosing and long-term medical guidance.



Medical Weight Management at Nee Soon Clinic

Patients considering tirzepatide can benefit from an individual medical review. At Nee Soon Clinic, a weight-management assessment may include weight and waist measurements, blood pressure, blood sugar and diabetes risk, cholesterol and cardiovascular risk, a review of current medication, side-effect assessment, nutrition and activity planning, muscle-preservation strategies, and a personalised treatment plan with follow-up.


To discuss whether the two-month medical weight-loss programme is appropriate for you, WhatsApp Nee Soon Clinic. Learn more about our medical weight-loss programme.


Tirzepatide is a prescription medication. Suitability, dosing and treatment duration should be determined with a qualified medical practitioner.


Not sure about your eligibility?

WhatsApp us

References

  1. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine, 2025. (SURMOUNT-5)

  2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. (SURMOUNT-1)

  3. Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 2024.

  4. Singapore National Drug Formulary. Tirzepatide: dosing, dose escalation and administration information.

  5. World Health Organization. Guideline on GLP-1 Therapies for the Long-Term Treatment of Obesity, 2025.


Official references: https://mounjaro.lilly.com/ and https://www.wegovy.com/



Related reading

tirzepatide weight loss: most googled questions


Disclaimer: The information provided in this article is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. The content is not intended to be a comprehensive source of information and should not be relied upon as such. Reliance on any information provided in this article is solely at your own risk. The authors and the publisher do not endorse or recommend any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned in the article. Any reliance on the information in this article is solely at the reader's own risk.

779 Yishun Ave 2, #01-1547, Singapore 760779

Tel: 6721 9796

779 Yishun Ave 2, #01-1547, Singapore 760779

Tel: 6721 9796

© 2026 by Nee Soon Clinic

bottom of page